本文選題：胃癌 + RBMS3　； 參考：《安徽醫(yī)科大學》2017年碩士論文

【摘要】：背景:RNA結合基序,單鏈相互作用蛋白3(RNA binding motif,single stranded interacting protein 3,RBMS3)是Myc單鏈作用結合蛋白(MSSPs)家族中的一員,其可編碼RNA結合蛋白,家族成員依次為RBMS1-3。研究表明RBMS3在少數鱗狀細胞癌中發(fā)揮抑癌作用,而其在胃癌中的表達情況及作用機制仍不清楚。分泌型卷曲相關蛋白(Secreted frizzled-related protein,SFRP)家族擁有5個成員,依次為SFRP1-5。SFRP1作為Wnt/β-catenin通路拮抗劑,在多腫瘤中發(fā)揮抑癌作用。研究發(fā)現RBMS3與SFRP1均可通過下調c-Myc和β-catenin抑制腫瘤的發(fā)生發(fā)展。目的:檢測人胃癌組織、對應癌旁正常組織中RBMS3及SFRP1的表達水平,明確RBMS3及SFRP1在胃癌中的表達情況,分別探索RBMS3及SFRP1的表達水平與胃癌的臨床參數之間的關系,并分析在胃癌組織中RBMS3及SFRP1表達水平之間的相關性,及兩者表達水平與胃癌患者預后的相關性,進而為進一步研究RBMS3及SFRP1在胃癌的發(fā)生發(fā)展中可能機制提供理論基礎。方法:收集新鮮人胃癌組織(23例)、對應的癌旁組織(23例),另收集172例胃癌組織及43例癌旁組織制成組織芯片。應用實時熒光定量逆轉錄-聚合酶鏈反應(q RT-PCR)檢測23對新鮮組織中RBMS3及SFRP1 m RNA的表達水平,同時應用蛋白免疫印跡(Western blot,WB)技術檢測RBMS1及SFRP1的蛋白表達水平。進一步運用免疫組化(Immunohistochemical,IHC)檢測172例胃癌組織及43例癌旁組織中RBMS3及SFRP1蛋白的表達水平。結果:胃癌組織、癌旁組織中RBMS3及SFRP1均有表達;RBMS3及SFRP1在胃癌組織中的表達水平明顯均低于其在癌旁正常組織(P0.05),RBMS3與SFRP1在胃癌組織中的表達水平(m RNA和蛋白)呈正相關;RBMS3在胃癌中的蛋白表達水平與胃癌的分化程度、浸潤深度顯著相關,SFRP1在胃癌中的蛋白表達水平與胃癌的分化程度顯著相關;RBMS3與SFRP1在胃癌中的蛋白表達水平均與胃癌患者預后相關,且兩者共表達水平是胃癌患者的獨立預后因子。結論:1、RBMS3及SFRP1在胃癌組織、癌旁組織中差異表達;2、RBMS3及SFRP1在胃癌組織中的表達水平呈正相關;3、RBMS3及SFRP1低表達的胃癌患者腫瘤分化程度差、預后差;4、RBMS3及SFRP1共表達水平可能是胃癌患者預后的一個有價值的生物學指標。
[Abstract]:Background: 3(RNA binding motifus single stranded interacting protein 3 (RBMS3) is a member of the Myc single-stranded binding protein (Myc) family, which encodes RNA binding proteins, and the family members are RBMS1-3. The results show that RBMS3 plays an inhibitory role in a small number of squamous cell carcinomas, but its expression and mechanism in gastric cancer are still unclear. There are five members of secreted frizzled-related protein family, SFRP1-5.SFRP1 as Wnt/ 尾 -catenin pathway antagonist, which plays a role of tumor suppressor in many tumors. It was found that both RBMS3 and SFRP1 inhibited tumor progression by down-regulating c-Myc and 尾-catenin. Objective: to detect the expression of RBMS3 and SFRP1 in human gastric cancer tissues, corresponding to the normal tissues adjacent to gastric cancer, to determine the expression of RBMS3 and SFRP1 in gastric cancer, and to explore the relationship between the expression of RBMS3 and SFRP1 and the clinical parameters of gastric cancer. The relationship between the expression of RBMS3 and SFRP1 in gastric cancer and the relationship between the expression of RBMS3 and SFRP1 and the prognosis of gastric cancer were analyzed, which provided a theoretical basis for the further study of the possible mechanism of RBMS3 and SFRP1 in the development of gastric cancer. Methods: 23 cases of fresh human gastric carcinoma tissues and 23 cases of adjacent tissues were collected. 172 cases of gastric cancer tissues and 43 cases of adjacent tissues were made into tissue microarray. The expression levels of RBMS3 and SFRP1 m RNA in 23 fresh tissues were detected by real-time fluorescence quantitative reverse transcription-polymerase chain reaction (RT-PCR), and the protein expression levels of RBMS1 and SFRP1 were detected by Western blotblotWB technique. The expression of RBMS3 and SFRP1 protein in 172 cases of gastric carcinoma and 43 cases of paracancerous tissues were detected by immunohistochemical staining (IHC). Results: gastric cancer tissue, The expression levels of RBMS3 and SFRP1 in gastric cancer tissues were significantly lower than those in adjacent normal tissues (P 0.05) and SFRP1 in gastric cancer tissues. There was a positive correlation between RBMS3 and SFRP1 in eggs of gastric cancer. The level of white expression and the degree of differentiation of gastric cancer, The expression of SFRP1 protein in gastric carcinoma was significantly correlated with the differentiation of gastric cancer. Both the expression of RBMS3 and SFRP1 in gastric carcinoma were correlated with the prognosis of gastric cancer. The coexpression level is an independent prognostic factor in patients with gastric cancer. Conclusion the differential expression of RBMS3 and SFRP1 in gastric cancer tissues and paracancerous tissues is positively correlated with the low expression of RBMS3 and SFRP1 in gastric cancer. The coexpression of RBMS3 and SFRP1 may be a valuable biological marker for the prognosis of gastric cancer patients.
【學位授予單位】：安徽醫(yī)科大學
【學位級別】：碩士
【學位授予年份】：2017
【分類號】：R735.2

【參考文獻】

相關期刊論文 前1條

1 ;Hypermethylation and aberrant expression of Wnt antagonist secreted frizzled-related protein 1 in gastric cancer[J];World Journal of Gastroenterology;2007年15期

，

本文編號：1935544